Alzheimer's disease, a devastating neurodegenerative condition that affects millions of people worldwide, may have found a ...

It is estimated that about 50% of atherosclerotic cardiovascular disease is not driven by LDL-cholesterol – the target of most lipid-lowering drugs, including statins and PCSK9 inhibitors like ...

For an exclusive license to the preclinical Lp(a) disruptor, AstraZeneca is paying CSPC Pharmaceutical Group $100 million ...

H ealth outcomes in humans often show daily variations. For instance, morning vaccinations may trigger a more effective ...

Homozygous familial hypercholesterolaemia (HoFH), a rare condition that affects about one in 300 000 individuals worldwide, ...

Despite uncertainty around who will sit in The White House in January and what ramifications they may bring, the industry’s ...

Our concepts of the pathogenesis of acute coronary syndromes have evolved considerably over time. Our concepts about the acute coronary syndromes have evolved markedly since the founding of the ...

Obicetrapib was tested as a monotherapy and in combination with lipid-lowering medications like statins. The topline results from the pivotal BROOKLYN trial were announced in July 2024.

AstraZeneca on Monday said it will pay up to $2 billion to license a cardiovascular drug.

DelveInsight’s, “Peripheral Arterial Disease Pipeline Insight 2024” report provides comprehensive insights about 18+ ...